key: cord-0300129-kpyaiym5
authors: Rennert, L.; Ma, Z.; McMahan, C.; Dean, D.
title: Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study
date: 2022-05-07
journal: nan
DOI: 10.1101/2022.05.06.22274771
sha: 819a5887cdb9b2e3ee347ead26acc5708c4e6b46
doc_id: 300129
cord_uid: kpyaiym5

Objective: To estimate the effectiveness of 2-dose and 3-dose mRNA vaccination (BNT162b2 and mRNA-1273) against any SARS-CoV-2 infection (asymptomatic or symptomatic) caused by the omicron variant. Design: Propensity-score matched retrospective Cohort Study. Setting: Large public university undergoing weekly Covid-19 testing in South Carolina, USA. Participants: Population consists of 24,145 university students and employees undergoing weekly Covid-19 testing between January 3rd and January 31st, 2022. The analytic sample was constructed via propensity score matching on vaccination status: Unvaccinated, completion of 2-dose mRNA series within previous 5 months, and receipt of mRNA booster dose within previous 5 months. The resulting analytic sample consists of 1,944 university students and 658 university employees. Intervention: Vaccination with a two dose or 3 dose regimen of the BNT162b2 or mRNA-1273 vaccine. Results: Booster protection against any SARS-CoV-2 infection was 66.4% among employees (95% CI: 46.1-79.0%; P<.001) and 45.4% among students (95% CI: 30.0-57.4%; P<.001). Compared to the 2-dose mRNA series, estimated increase in protection from the booster dose was 40.8% among employees (P=.024) and 37.7% among students (P=.001). We did not have enough evidence to conclude a statistically significant protective effect of the 2-dose mRNA vaccination series, nor did we have enough evidence to conclude that protection waned in the 5-month period after receipt of the 2nd or 3rd mRNA dose. Furthermore, we did not find evidence that protection varied by manufacturer. Conclusions: Covid-19 mRNA booster doses offer moderate protection against any SARS-CoV-2 infection caused by the omicron variant and provide a substantial increase in protection relative to the 2-dose mRNA vaccination series.

The B.1.1529 (omicron) variant of Severe Acute Respiratory Syndrom Coronavirus 2 (SARS-CoV-2), first detected in South Africa in November 2021, is more infectious than any previous variant of SARS-CoV-2. 1 Omicron has caused record number of daily SARS-CoV-2 infections in the United States (US) and world wide. 2 Preliminary studies suggest Covid-19 vaccines have lower neutralization efficacy against omicron and are less protective against hospitalization. 3, 4 However, data on the extent to which Covid-19 vaccines are protective against general infection from omicron, including asymptomatic, presymptomatic, and symptomatic infection, is limited.

While SARS-CoV-2 infections caused by the omicron variant are associated with a reduced risk of severe disease compared to previous variants, 5 high infection rates increase the risk of severe disease for the population as a whole. Protection against any SARS-CoV-2 infection is therefore important for reduction of both individual and community risk. In this study, we assess effectiveness of the 2-dose and 3-dose messenger RNA (mRNA) vaccination series approved by the U.S. Food and Drug Adminstration (FDA), BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), in a large public university student and employee population undergoing mandatory weekly testing during the Spring 2022 semester. Because such screening captures all infections (including asymptomatic and pre-symptomatic), this study setting is ideal for evaluation of protection against any SARS-CoV-2 infection.

The study population consists of students and employees undergoing mandatory weekly testing between January 3 rd and January 31 st at Clemson University in South Carolina (SC). The study sample was restricted to youngadult students between 18 and 24 years and university employees between 18 and 64 years. Exclusion criteria is provided in Figure 1 , and consists of student athletes, recipient of a vaccine dose other than BNT162b2 or mRNA-1273, individuals receiving the second dose of BNT162b2 less than 21 days after their first dose or . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint second dose of mRNA-1273 less than 28 days after first dose, recipient of a booster dose less than 5 months after the second dose of the mRNA-1273 or BNT162b2, and individuals with invalid vaccination cards. Per surveillance testing protocols, individuals testing positive were not required to partake in mandatory pre-arrival or surveillance testing for 90 days since the original positive test result, and are therefore excluded from analyses. 6 Individuals who have self-reported conditions impacting immune response, including HIV, cancer, lupus, rheumatoid arthritis, or solid organ or bone marrow transplant, and who have self-reported medication use of steroids, chemotherapy, or immunosuppressants, were excluded from the sample. Students vaccinated prior to 7 Individuals also had the option to upload information on booster doses at any point. While this was encouraged through university communications, financial incentives were not offered for booster upload. Vaccination data includes vaccine manufacturer and administration dates of first, second, and booster doses.

Individuals who were not affiliated with the University during the Fall 2021 semester were excluded from analyses, since this population was not eligible to participate in the University's financial incentive program for voluntary upload of Covid-19 vaccination and is therefore subject to underreporting. The incentive program only required proof of full vaccination (e.g., completion of 2-dose mRNA series). Many individuals likely received a booster dose after uploading proof of full vaccination. Because financial incentives were not offered for booster upload, those reporting full vaccination likely contain a mixture of individuals completing the 2-dose and 3-dose mRNA vaccination series. From the fully vaccinated cohort (i.e., people reporting only a 2-dose mRNA . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint vaccination series), we excluded all individuals who received their 2 nd dose more than 5 months prior to the end of the follow-up (Jan 31 st , 2022). This ensures that the resulting fully vaccinated cohort would be devoid of boosted individuals since its constituents would not be eligible to receive the mRNA booster dose during the study period.

Vaccination status was coded as partially vaccinated if 14-days had passed since the first dose of mRNA-1273 or BNT162b2, fully vaccinated if at least 14 days had passed since the second dose of BNT162b2 or mRNA-1273, 8 and boosted if 7 days had passed since the receipt of a the BNT162b2 or mRNA-1273 booster dose. 9 The analytic sample was restricted to individuals reporting no vaccination, completion of the 2-dose mRNA vaccination series within 5 months of end of follow-up (fully vaccinated), and receipt of an mRNA booster dose (boosted).

Pre-arrival testing was required for all individuals between January 3 rd and January 12 th (in-person instruction), followed by weekly surveillance testing. Residential students were also required to test upon arrival to residence halls (beginning January 9 th ). All students had the option of receiving a SARS-CoV-2 test on campus or obtaining their test elsewhere and uploading their result to the University's Covid-19 test upload portal. Accepted methods included nasal, throat, or saliva-based polymerase-chain-reaction (PCR) tests. 10 11, 12 Testing was mandated for all universityaffiliated individuals; access to campus facilities was restricted until a negative test result was obtained. Prearrival and surveillance testing protocols for previous semesters, including clinical descriptions of testing procedures, are described elsewhere. 6, 11 It is estimated that 99.2% of all SARS-CoV-2 infections in South Carolina were caused by the omicron variant in January of 2022. 13 Propensity Score Matching . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint Propensity-score matching was used to adjust for confounding of vaccine effectiveness estimates due to reporting bias and differences in health-seeking behavior. To achieve covariate balance while preserving sample size, matching was conducted using a common-referent approach. 14 In the student sample, 1:1 nearest neighbor caliper matching was conducted between boosted and fully vaccinated individuals and 1:2 nearest neighbor caliper matching was conducted between boosted and unvaccinated individuals. 15, 16 The post-matched student sample consists of unvaccinated and fully vaccinated individuals who had a common match with a boosted individual. 14 In the employee study sample, 1:4 nearest neighbor caliper matching was conducted between fully vaccinated and boosted individuals and 1:4 nearest neighbor caliper matching was conducted between fully vaccinated and unvaccinated individuals. The post-matched employee sample consists of boosted and unvaccinated individuals who had a common match with a fully vaccinated individual. The caliper width was set to 0.20 times the standard deviation of the logit of the propensity scores. 17 Variables in the propensity score model included age, sex, affiliation (students: residential or non-residential living, employees: faculty or staff), graduate student status (students only), race/ethnicity, self-reported pre-existing conditions (high blood pressure, heart disease, diabetes, overweight or obesity, kidney disease or dialysis, previous stroke or other neurological condition affecting ability to cough, liver disease, or lung disease), use of tobacco or nicotine products, number of SARS-CoV-2 tests in Fall 2020, Spring 2021, and Fall 2021 semesters, and history of previous SARS-CoV-2 infection.

Demographic and clinical characteristics are provided for the analytic sample and stratified by vaccination status in Table 1A /B. Differences between unvaccinated, fully vaccinated, and boosted individuals were assessed using ANOVA for continuous variables and chi-squared tests for categorical variables. Time-varying Cox proportional hazard models were used to estimate the relative risk (RR) of SARS-CoV-2 infection by vaccination status during the follow-up period (1/3/2022-1/31/2022). The outcome was days between start of follow-up and date of first SARS-CoV-2 positive test (event date). Individuals who did not test positive during the follow-up period were right censored at their last negative test date (censoring date). Vaccination status was modeled as a time-varying exposure variable. Because university students tend to engage in high-density social interactions which result in . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint exposure to higher viral loads, 18 models were run independently for student and employee populations. We adjust for all potential confounders included in the propensity score models to account for residual imbalance after matching. 19 Specifically, models were adjusted for previous SARS-CoV-2 infection history, age, race, gender, residential status, self-reported pre-existing conditions, use of nicotine or other smoking products, and number of previous SARS-CoV-2 tests (surrogate for health-seeking behavior). 20, 21 Vaccine effectiveness was estimated by 1-RR. 6 Overall mRNA vaccine protection was estimated via Model 1.1 (Appendix 1). Effectiveness by vaccine manufacturer was estimated via Model 1.2 (Appendix 1).

To evaluate vaccine effectiveness by previous infection history, an interaction term between vaccine status and previous infection was included in separate models (Appendix 1, Models 1.3-1.4). To account for heavy censoring of event times, we apply Firth's penalized likelihood method. 22 

Descriptive characteristics for students and employees in the post-matching analytic sample are presented in Table   1A /B. This sample consists of 1,944 students who were tested for Covid-19 during the follow-up period, of which 954 did not report any vaccination (49.0%), 495 reported full vaccination (25.5%), and 495 reported receiving a booster dose (25.5%). The average age of this population was 19.64 years (SD=1.42). The majority of the population was non-Hispanic White (81.3%), female (66.4%), lived in residential housing (50.7%), did not report any pre-existing condition (97.0%), did not use tobacco or nicotine products (98.1%), and did not have a previous SARS-CoV-2 infection (77.2%). The average number of SARS-CoV-2 tests per person was 30.61 (SD=11.96). Statistically significant differences were observed in the proportion of residential students (boosted: 48.7%, fully vaccinated: 45.7%, unvaccinated: 54.3%, P = .005) and the number of SARS-CoV-2 tests during the Spring 2022 semester (boosted: 4.24, fully vaccinated: 3.34, unvaccinated: 3.17, P < .001). However, the latter variable was . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint not included in the propensity score models since it is strongly correlated with the outcome (due to the 90-day exemption from mandatory testing after a positive result). In total, 28.3% of individuals tested positive during the follow-up period. Positivity rates were significantly lower (P < .001) among boosted individuals (16.2%) compared to fully vaccinated (34.5%) and unvaccinated individuals (31.3%).

The post-matching analytic sample for employees consists of 658 individuals who were tested for Covid-19

during the follow-up period, of which 342 did not report any vaccination (52.0%), 87 reported full vaccination The matching protocol substantially improved balanced on most variables, as measured by standardized differences pre-and post-matching ( Figure S1A/B) . Using a threshold of standardized differences < 0. 25, 23 balance was achieved on 100% and 95.5% of pairwise comparisons between all variables for students and employees, respectively. Using a threshold of 0.10, 19,23 balance was achieved on 86.3% and 60.0% of pairwise comparisons. For employees, the lower proportion is due to, at least in part, the small sample size for fully . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint vaccinated individuals. 19 Residual imbalance is adjusted for through inclusion of all confounders in the models for vaccine effectiveness. 19 

Estimates of vaccine effectiveness for students and employees are presented in Table 2A Differences between booster manufacturers were not statistically significant for students (P = .652) or employees (P = .417). Furthermore, statistically significant differences were not observed between individuals who mixed and matched (i.e., 2-dose primary series and booster dose from different manufacturers) and those completing the 3-dose BNT16b2 sequence (students: P = .360, employees P = .985), or those completing the 3-dose mRNA-1273 sequence (students: P = .353, employees: P = .589). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; 1 0 employees (95% CI: 0.66-3.46, P =.324); however, we did not have enough evidence to conclude statistical significance for the latter effect.

We did not have evidence to conclude that mRNA vaccine protection varied by previous infection history. 

In this study setting, 21.4% of university employees and 28.3% of university students tested positive for SARS-CoV-2 during a 4-week period in which omicron was the dominant SARS-CoV-2 variant. The mRNA booster dose offered moderately high protection for employees (66.4%) and moderate protection for students (45.4%) against any SARS-CoV-2 infection caused by the omicron variant. Furthermore, estimated protection from the mRNA vaccine booster dose was approximately 40% higher for both students and employees relative to the 2dose mRNA vaccine series.

We did not have enough evidence to conclude that the 2-dose mRNA series was protective against general SARS-CoV-2 infection from the omicron variant. Compared to our study, recent studies have found higher 2-dose and 3dose mRNA vaccine effectiveness against symptomatic and severe SARS-CoV-2 infection from omicron. 3, 24, 25 This is to be expected, since this study evaluates protection against any SARS-CoV-2 infection from omicron (asymptomatic, pre-symptomatic, and symptomatic) as opposed to severe infection. While protection against severe SARS-CoV-2 infection is the primary objective of Covid-19 vaccination, protection against general . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint 1 infection is important for mitigating community transmission, since asymptomatic and pre-symptomatic individuals are substantial contributors to disease spread. 26 Therefore, less protection against general infection increases the risk for all individuals in the population. Taken together, this study and others provide evidence that booster shots are beneficial for both individual health and reduction in community transmission. 27,28

On the surface, our findings of higher protection in older university employees relative to younger university students appear to contradict evidence that Covid-19 vaccines are (relatively) less protective in older adults. 29, 30 However, the risk of infection is dependent on the size of the infecting dose of the virus (i.e., viral load). [31] [32] [33] [34] [35] [36] Compared to the average adult, university students typically engage in more frequent and higher-density social interactions. 18, 37 Such social behavior increases exposure to higher viral loads and subsequently impacts the protective effect of vaccines.

Due to mandated weekly testing, this study design is well-suited for evaluating vaccine effectiveness against any SARS-CoV-2 infection caused by Omicron. Based on the temporal dynamics in SARS-CoV-2 viral shedding, 38, 39 most cases were likely detected since the start of January. Mandatory testing also reduces the risk of confounding that may occur in clinical populations due to differences in risk-seeking behavior. 40 Relative to the general population, there is a higher degree of homogeneity in this study sample of university students and employees.

This feature, combined with stratification by affiliation (student, employee), propensity score matching, and covariate adjustment based on demographics, occupation, clinical characteristics, and health-seeking behavior, further reduces the risk of confounding in this study.

Our study is subject to several limitations. First, due to low variability in month of vaccination in our study sample and a relatively short follow-up period, there was insufficient power to assess waning vaccine immunity after the 2 nd and 3 rd dose against any SARS-CoV-2 infection caused by omicron. Second, the omicron surge in South Carolina began at least one week before arrival testing was initiated. 41 While underreporting of infections prior to this period was less likely for symptomatic individuals (proof of a positive SARS-CoV-2 test provided a . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Messenger RNA (mRNA) booster doses offer moderate protection against general SARS-CoV-2 infection caused by the omicron variant. In both university students and employees, receipt of the mRNA booster dose substantially increased protection relative to the 2-dose mRNA vacccination series. The effectiveness of mRNA boosters on both individual health and reduction in community transmission support continued efforts for Covid-19 booster doses. This is especially important in the young-adult population, which has suboptimal vaccine uptake yet is a major contributor to community spread. However, given that approximately one-third to one-half of the study population remains susceptible to breakthrough infection, certain precautions after vaccination may still be warranted.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint 1 6 1 7 Self-reported presence of any of the following conditions: high blood pressure, heart disease, diabetes, overweight or obesity, kidney disease or dialysis, previous stroke or other neurological condition affecting ability to cough, liver disease, or lung disease; sample size may not add to N due to non-selection of specific conditions. ¶ During follow-up period (1/3/2022 to 1/31/2022) † Infection occurring prior to follow-up period (1/3/22) # % is proportion of individuals within each population infected with SARS-CoV-2 during follow-up period * Variable not included in propensity score model . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. Self-reported presence of any of the following conditions: high blood pressure, heart disease, diabetes, overweight or obesity, kidney disease or dialysis, previous stroke or other neurological condition affecting ability to cough, liver disease, or lung disease; sample size may not add to N due to non-selection of specific conditions. ¶ During follow-up period (1/3/2022 to 1/31/2022) † Infection occurring prior to follow-up period (1/3/22) # % is proportion of individuals within each population infected with SARS-CoV-2 during follow-up period * Variable not included in propensity score model . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.06.22274771 doi: medRxiv preprint

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet. 2021;0(0)

Covid-19: Omicron drives weekly record high in global infections

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Clinical Outcomes among Patients Infected with Omicron (B.1.1.529) SARS-CoV-2 Variant in Southern California

Risk of SARS-CoV-2 reinfection in a university student population

Clemson Announces Incentives for Proof of Vaccine Uploads

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet

Clemson announces testing and health requirements for the Spring semester return · Clemson News

Surveillance-based informative testing for detection and containment of SARS-CoV-2 outbreaks on a public university campus: an observational and modelling study. The Lancet Child & Adolescent Health

SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity

Matching by Propensity Score in Cohort Studies with Three Treatment Groups: Epidemiology

Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score

Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

Modelling the impact of presemester testing on COVID-19 outbreaks in university campuses

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Collider bias undermines our understanding of COVID-19 disease risk and severity

Risk-taking unmasked: Using risky choice and temporal discounting to explain COVID-19 preventative behaviors

A solution to the problem of monotone likelihood in Cox regression

Prognostic score-based balance measures for propensity score methods in comparative effectiveness research

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

SARS-CoV-2 transmission from people without COVID-19 symptoms

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

COVID-19: disease, or no disease? -that is the question. It's the dose stupid! Microbes and Infection

COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? Medical Hypotheses

Reducing risks from coronavirus transmission in the home-the role of viral load

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases

Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study

Certainty of success: three critical parameters in coronavirus vaccine development. npj Vaccines

Mass testing of university students for covid-19

Ending Isolation and Precautions for People with COVID-19: Interim Guidance

Temporal dynamics in viral shedding and transmissibility of COVID-19

We thank the Clemson University administration, medical staff, and all other testing